Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has announced the closing of its non-brokered private placement with Sorbie Bornholm LP and Sorbie Investments LLP, securing a notional subscription amount of approximately CAD$5 million. The financing, structured as an 18-month sharing arrangement tied to the volume-weighted average trading price of the company's shares, involved the issuance of 7.94 million units at a notional price of CAD$0.63 per unit. Each unit consists of one common share and one warrant exercisable at CAD$0.77 for three years. The proceeds will be made available through monthly settlement amounts that vary based on market performance.
Onco-Innovations intends to use the net proceeds to advance development of its ONC010 program, including manufacturing and preclinical activities, support continued development of its SynoGraph platform, and provide working capital for general corporate purposes. The ONC010 program targets solid tumors through patented technology for which the company holds an exclusive worldwide license. The SynoGraph platform is designed to enhance drug delivery and efficacy in oncology treatments.
This capital injection is significant for Onco-Innovations as it transitions from research to development phases. The company, dedicated to cancer research and treatment, is leveraging this funding to move its lead programs closer to clinical trials. The structured financing arrangement also provides flexibility, aligning investor returns with company performance. For more details, the full press release is available at https://ibn.fm/1Hrlg.
The completion of this private placement underscores investor confidence in Onco-Innovations' approach to oncology. The funds will enable the company to accelerate preclinical work and manufacturing, potentially expediting the path to market for novel solid tumor therapies. As the company progresses, updates will be shared via its newsroom at https://ibn.fm/ONNVF.
This development is important because it provides Onco-Innovations with the necessary resources to advance its oncology pipeline, addressing the significant unmet need for effective solid tumor treatments. The successful closing also highlights the viability of alternative financing structures in the biotech sector.
